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Use of the second-generation antipsychotic, risperidone, and
secondary weight gain are associated with an altered gut
microbiota in children
SM Bahr1, BC Tyler2, N Wooldridge2, BD Butcher2, TL Burns3, LM Teesch4, CL Oltman5, MA Azcarate-Peril6, JR Kirby1 and CA Calarge2,7
The atypical antipsychotic risperidone (RSP) is often associated with weight gain and cardiometabolic side effects. The mechanisms
for these adverse events are poorly understood and, undoubtedly, multifactorial in etiology. In light of growing evidence
implicating the gut microbiome in the host’s energy regulation and in xenobiotic metabolism, we hypothesized that RSP treatment
would be associated with changes in the gut microbiome in children and adolescents. Thus, the impact of chronic (412 months)
and short-term use of RSP on the gut microbiome of pediatric psychiatrically ill male participants was examined in a cross-sectional
and prospective (up to 10 months) design, respectively. Chronic treatment with RSP was associated with an increase in body mass
index (BMI) and a significantly lower ratio of Bacteroidetes:Firmicutes as compared with antipsychotic-naïve psychiatric controls
(ratio = 0.15 vs 1.24, respectively; Po0.05). Furthermore, a longitudinal observation, beginning shortly after onset of RSP treatment,
revealed a gradual decrease in the Bacteroidetes:Firmicutes ratio over the ensuing months of treatment, in association with BMI
gain. Lastly, metagenomic analyses were performed based on extrapolation from 16S ribosomal RNA data using the software
package, Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt). Those data indicate that
gut microbiota dominating the RSP-treated participants are enriched for pathways that have been implicated in weight gain, such
as short-chain fatty acid production.
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INTRODUCTION
Over the last two decades, the prescribing rate of second-
generation antipsychotic medications (SGAs) to treat children has
increased nearly eightfold, in light of evidence supporting their
efficacy.1–3 However, significant weight gain and associated
cardiometabolic disturbances are common side effects, placing
patients at an elevated risk for type 2 diabetes and cardiovascular
disease.1,4–6 Alarmingly, the life expectancy of patients with severe
mental illness is 20–25 years shorter than that of the general
population, primarily due to increased cardiovascular disease.7–9
The mechanisms underlying SGA-induced weight gain are not
well understood. The metabolic side effects are believed to be
multifactorial in their etiology, including pharmacological, genetic,
lifestyle and environmental contributors.10–12 Recent evidence
also implicates the gut microbiome, which impacts various aspects
of metabolism, including energy harvest and the development of
obesity.3,13–17 Davey et al. have shown that acute olanzapine
treatment in rats resulted in significant weight gain and
cardiometabolic dysfunction in association with changes in the
gut microbiota.1–3 Importantly, mice lacking a microbiota do not
gain as much weight compared with non-treated controls.18
The interaction between the gut microbiota and SGAs may well
be bidirectional. In fact, gut bacteria utilize neurotransmitter
signaling pathways targeted by antipsychotic medications.19–21 On
the other hand, they have a substantial role in xenobiotic
pharmacokinetics. For example, the cleavage of the benzisoxazole
ring system of risperidone (RSP) is a process effected primarily by
the intestinal microbiota, yielding alternative metabolites.7
Microbiota-mediated mechanisms such as these can contribute to
the emergence of adverse drug events, including weight gain.7–9,22
In contrast to olanzapine, whose use in adolescents has been
discouraged by the Food and Drug Administration due to its
propensity to cause significant weight gain,10–12 RSP is one of the
most commonly prescribed SGAs, particularly in children and
adolescents.2,3 RSP is, nonetheless, associated with a moderately
high potential to induce weight gain.4 Thus, we performed a cross-
sectional examination of the impact of chronic RSP exposure in
children and adolescents on gut bacterial composition and on the
corresponding metabolic pathways. We further explored the
longitudinal dynamics of the gut microbiota following the onset
of RSP treatment. Our results indicate that RSP use is associated
with alteration of the gut microbiome that is enriched for
metabolic pathways that might cause or exacerbate weight gain.
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The cross-sectional study involved 18, 9–15-year-old, medically healthy
males who had been on RSP for at least 1 year (chronic RSP group). The
longitudinal study consisted of five males, aged 9–13 years, enrolled within
1 month of starting RSP. Ten 10–14-year-old participants, who were
psychiatrically ill but not receiving any SGAs, served as controls. Height and
weight were measured following standard guidelines during the research
visits.23 Body mass index (BMI) was calculated and age–sex-specific BMI
Z-scores were computed to account for natural growth.24 When available,
anthropometric data were also extracted from the medical records to
compute baseline BMI Z-score for RSP-treated participants within − 31 to
+3 days of RSP initiation.23 This allowed estimating the change in BMI
Z-score between the time RSP was started and study visit. In order to do
the same for the psychiatric control group, baseline BMI measurements
were determined from the medical records to provide a comparable
mean± s.d. interval between baseline BMI and BMI at time of stool sample
collection across treatment groups. Stool samples were collected once in the
cross-sectional study, and as frequently as every month in the longitudinal
study. Stool samples were collected freshly and transported to the lab where
they were aliquoted and frozen within 15–30min. Alternatively, they were
provided at home, placed on dry ice supplied by research staff and picked
up within 24 h (while still frozen). Samples were stored at − 80 °C until DNA
extraction and were excluded from the study when antibiotic use occurred
within 6 months of sample collection. The studies were approved by the
Institutional Review Board at the University of Iowa.
Multiplex DNA sequencing and assembly
Extracted genomic DNA was subjected to multiplex paired-end Illumina
(Illumina, San Diego, CA, USA) sequencing of the V1-2 region of bacterial
16S ribosomal RNA (rRNA) genes with a MiSeq instrument (Chapel Hill, NC,
USA) in the UNC Microbiome Core Facility. See Supplemental Methods for
further details about the analysis.
RESULTS
Eighteen male participants, mean age 12.2 (s.d. = 2.5) years,
provided stool samples for the cross-sectional study, after a mean
of 3.6 (s.d. = 2.4) years of RSP treatment. In addition to RSP,
participants also used psychostimulants (n= 18, 100%), α-2
agonists (n= 12, 66%) and selective serotonin reuptake inhibitors
(n= 2, 11%). Over the course of treatment, BMI Z-score increased
by a mean of 0.31 (s.d. = 1.11) points. Ten boys who had not
received RSP served as psychiatric controls. Their mean age was
12.0 (s.d. = 1.8) years. They were taking psychostimulants (n= 7,
70%), α-2 agonists (n= 3, 30%) and selective serotonin reuptake
inhibitors (n= 2, 20%). Over a comparable time interval (see
Methods section), their BMI Z-score remained virtually unchanged
(mean ΔBMI Z-score = 0.09, s.d. = 0.61). Psychiatric diagnoses and
gastrointestinal symptoms were not different between the two
groups, nor was food intake (Supplementary Table 1).
The longitudinal study consisted of five participants aged between
9 and 13 years (mean=11.7, s.d. = 1.1), with a mean BMI Z-score at
study entry of 0.12 (s.d. = 0.84). Participants provided a stool sample
within a few days (mean=3.2, s.d. = 5.2) of starting RSP treatment
and then up to monthly, for 10 months. Over the course of the
treatment, BMI Z-scores increased by a mean of 0.28 (s.d. = 0.23)
units. All five participants were additionally taking psychostimulants
and three of them (60%) were also taking α-2 agonists.
Chronic RSP treatment is associated with a distinct gut
microbiome
To evaluate whether microbial diversity is altered during chronic
treatment with RSP, we surveyed fecal bacterial populations using
16S rRNA sequencing. The chronic RSP group displayed a
significantly higher Shannon diversity when compared with
psychiatric control participants (5.9 vs 5.2, respectively, Po0.05;
Supplementary Figures 1A and B). There was a higher phyloge-
netic diversity (P= 0.05; Supplementary Figures 1C and D) as well
as a numerically, but not statistically, increased number of
observed species in psychiatric control participants (Supple-
mentary Figures 1E and F).
Using UniFrac, a phylogenetic distance metric, participants in
the chronic RSP group were significantly different from psychiatric
controls (analysis of similarity (ANOSIM) R= 0.516, Po0.05). This
indicates that a robust difference exists between the overall gut
microbial profiles of the two groups (Figure 1). However, using this
same metric among participants taking RSP, there was no
significant difference (ANOSIM R= 0.001, P= 0.41) in microbial
profiles between those who had a significant BMI gain (n= 10),
defined as a BMI Z-score increase by ⩾ 0.5 units, and those who
did not (n= 8; Supplementary Figure 2B).
Chronic and acute treatment with RSP are associated with weight
gain and alterations in gut bacterial composition
The most common bacterial phyla in healthy adults are Firmicutes
and Bacteroidetes, with significant representation of Actinobac-
teria and Proteobacteria. The relative proportions of these phyla
sometimes diverge widely, reflecting not only interpersonal,
geographical and lifestyle variations but also perturbations caused
by disease.25 In our study, the psychiatric control participants
displayed a distribution of the two major gut phyla, Firmicutes and
Bacteroidetes, comparable to that observed in healthy populations26
(Figure 2a and Supplementary Table 2). In contrast, participants
treated long-term with RSP and who also displayed a significant BMI
gain had significantly less Bacteroidetes than Firmicutes relative to
controls (ratio= 0.20 vs 1.24, respectively, Po0.05). Importantly,
significant differences in bacterial composition also differentiated
RSP-treated participants who exhibited significant BMI gain from
those who did not (Figure 2a and Supplementary Table 2). Finally,
the bacterial composition within each of the two RSP treatment
groups (regardless of changes in BMI Z-score) was different from
that found in psychiatric controls (Figure 2a and Supplementary
Table 2). Thus, both long-term RSP treatment as well as significant
RSP-related BMI gain are independently associated with an altered
distribution of the gut microbiota.
Figure 1. Differences in the fecal microbial communities in chronic
risperidone (RSP)-treated participants vs psychiatric controls. PcoA
of unweighted UniFrac distances between psychiatric control
participants (green), chronic RSP-treated participants with signifi-
cant body mass index (BMI) gain (blue, i.e., an increase in age− sex-
specific BMI Z-score⩾ 0.5 units since starting RSP), and RSP-treated
participants without significant BMI gain (yellow). Each point shows
the average distance between individuals. Results are derived from
bacterial V1−V2 16S rRNA data sets. ANOSIM R= 0.5169, P= 0.0001.
PCoA, principal component analysis.
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Data from sequential stool sampling revealed an increase in
Firmicutes relative to Bacteroidetes, apparent within 1–3 months
after initiating RSP treatment, that is, with the first follow-up stool
sample (Figure 2b). The trend became more prominent over a
longer period of exposure. Importantly, the percent abundance of
Firmicutes and Bacteroidetes appeared to correlate with the RSP-
induced increase in BMI Z-score, albeit not significantly, likely
owing to the small sample size (for Bacteroidetes: Spearman’s
r=− 0.29, P= 0.30; for Firmicutes: r= 0.32, P= 0.26; Figure 2c).
Discriminatory OTUs are detectable within treatment groups
associated with weight gain
Fifty key operational taxonomic units (OTUs) were identified as
sufficient to discriminate between psychiatric controls and chronic
RSP participants (Figure 3). Only three genera, belonging to the
phylum Bacteroidetes, were more abundant in the psychiatric
controls. In contrast, 47 OTUs were significantly more prevalent in
the RSP participants, the most abundant being Clostridium sp.,
Collinsella aerofaciens, Lactobacillus sp., Ralstonia sp. and the
Erysipelotrichaceae family.
Importantly, Clostridium sp., Lactobacillus sp., Ralstonia sp. and
Erysipelotrichaceae family members were more abundant in
participants in the chronic RSP group who also displayed a
significant BMI gain. In contrast, the order Coriobacteriales,
specifically C. aerofaciens, was more abundant in participants
within the chronic RSP group who did not show a significant BMI
gain. These results suggest that specific Firmicutes and Burkhol-
deriales species may have a role in RSP-induced weight gain while
Coriobacteriales may be protective. In addition, Ruminococcaceae
family members were most relatively abundant in RSP participants
with significant BMI gain compared with psychiatric controls,
whereas Bacteroidetes spp. were most relatively abundant in
psychiatric controls compared with RSP participants regardless of
BMI gain (Supplementary Figure 3).
Gene frequency reveals altered microbial metabolic functionality
following chronic treatment with RSP
To predict the potential consequences of altering microbial gut
composition in response to RSP treatment, we assessed the
metabolic capacity of the microbiota based on the presence of
Figure 2. Phyla-level abundances. (a) Phyla-level abundances in psychiatric controls (green), chronic risperidone (RSP)-treated participants
with significant body mass index (BMI) gain (blue, that is, an increase in age–sex-specific BMI Z-score ⩾ 0.5 units since starting RSP) and chronic
RSP-treated participants without significant BMI gain (yellow). (b) Trajectory of change over time in the two major gut bacterial phyla,
Bacteroidetes and Firmicutes, following the initiation of RSP. (c) Correlation of change in percent abundance of Bacteroidetes and Firmicutes,
and change in BMI Z-score following the initiation of RSP.
Figure 3. Relative abundance of unique genus-level operational
taxonomic units (OTUs) of the gut microbiota of chronic risperidone
(RSP)-treated participants and psychiatric controls. Fifty unique
OTUs were defined by three methods (Metastats comparison,
random forests algorithm and linear discriminant analysis effect
size analysis). Genus-level OTUs are colored by phyla (bottom, x-axis)
and individual biological replicates (left, green or blue), where red
hues denote increased relative abundance of a unique OTU. BMI,
body mass index.
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organisms discerned by 16S rRNA sequences utilizing the
algorithm, Phylogenetic Investigation of Communities by Recon-
struction of Unobserved States (PICRUSt).27 Overall, out of 6909
potential metabolic features, we found 1212 KEGG (Kyoto
Encyclopedia of Genes and Gene Systems) orthologs that were
significantly different between the two groups (Po0.05; Figure 4).
Families of KEGG orthologs were found to vary based on
treatment group using principal component analysis (Figure 4a).
By assigning KEGG orthologs to specific bacterial metabolic
pathways, it was revealed that participants in the chronic RSP
treatment group had microorganisms that were enriched for
environmental information processing pathways (for example,
response to antibiotics) and cellular processes (Figure 4b). In
contrast, psychiatric control participants had significantly more
orthologs classified in bacterial metabolism pathways (Figure 4b).
A more detailed analysis revealed that those pathways prominent
in the chronic RSP treatment group included membrane transport,
cell motility, xenobiotics biodegradation and metabolism, tran-
scription and signal transduction (Figure 4c). Within the xenobio-
tics biodegradation and metabolism category, major pathways
included butanoate, propanoate, fatty acid and tryptophan
metabolism (Figure 4c), all of which have been implicated in
weight gain.28,29 Conversely, pathways in greater abundance in
psychiatric controls included glycan biosynthesis and metabolism,
as well as metabolism of cofactors and vitamins. Here, glycan
biosynthesis comprises mostly lipopolysaccharide biosynthesis,
which is found primarily in Gram-negative organisms such as
Bacteroidetes spp. The latter were vastly decreased in the RSP
participants. Thus, PICRUSt reveals a potential mechanistic link
between the observed shifts in bacterial taxa and their
corresponding metabolic potential in response to treatment
with RSP.
Figure 4. Phylogenetic Investigation of Communities by Reconstruction of Unobserved States (PICRUSt) predicted KEGG (Kyoto Encyclopedia
of Genes and Gene Systems) orthologs. 1212 Significant KEGG orthologs were predicted with PICRUSt software. (a) PCoA of KEGG orthologs in
chronic risperidone (RSP)-treated participants vs psychiatric controls. (b, c) Global and individual KEGG pathways of chronic RSP-treated
participants (blue) vs psychiatric controls (green). PCoA, principal component analysis.
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DISCUSSION
To our knowledge, this is the first description of a shift in the
human gut microbiota following the use of SGAs. We found a
significant shift in Bacteroidetes and Firmicutes in participants
exposed chronically to RSP (76 and 11%, respectively) when
compared with psychiatric controls (51 and 41%, respectively). The
magnitude of these differences was most prominent in those
participants who had gained significant weight. These differences
in the gut microbiome composition following chronic treatment
are consistent with findings from the prospective study where
similar changes appeared to correlate with the magnitude of
change in BMI Z-score.
The long-term health sequelae of obesity are significant and
include cardiovascular disease and type 2 diabetes,30 particularly
when obesity develops in childhood. Pediatric patients suffering
from psychiatric disorders are at an elevated risk for obesity due to
disease-related factors; this was a primary reason for selecting as
controls participants with psychiatric illness but who are SGA
naive. Although pharmacotherapy is often unavoidable to address
serious symptoms and improve functioning, it is concerning that
SGAs induce weight gain, compounding the health risks
associated with obesity. SGA-induced weight gain is multifactorial
and it is likely that the gut microbiome is a key contributor. In fact,
a 3-week treatment with olanzapine induced weight gain in rats
and led to a 4.3% decrease in Bacteroidetes.1 Despite the
differences between the rat and human microbiomes, it is notable
that, similar to olanzapine-treated rats, our participants treated
chronically with RSP exhibited significantly lower relative prev-
alence of Bacteroidetes. Notably, a decrease in Bacteroidetes of a
comparable magnitude has been reported in obese individuals,
although the evidence is not without inconsistency.13,31 Impor-
tantly, our results from the longitudinal study provide preliminary
confirmation that a change in gut bacterial composition (including
a decrease in Bacteroidetes) follows the initiation of RSP treatment
and correlates with weight gain during the initial treatment phase.
Using Unifrac, which is an index of overall bacterial profile, we
found no significant association between those who exhibited
significant BMI gain and those who did not, following RSP
treatment (Figure 1). However, when individual phyla, genera and
species were compared, chronic RSP participants with a significant
BMI gain were found to harbor a unique set of organisms, which
distinguishes them from the chronic RSP participants without BMI
gain (Figure 2). Therefore, it would be critical to examine how
baseline microbial profile may shape one’s propensity to gain
weight following the initiation of SGAs.
To identify specific taxa that correlate with significant weight
gain following RSP treatment, we described discriminatory OTUs
associated with each treatment group (Figure 3). For psychiatric
controls, the discriminatory OTUs were attributable to the class
Bacteroidales. In contrast, for participants in the chronic RSP group
with significant BMI gain, Ralstonia sp., Clostridium sp. and
members of the Erysipelotrichaceae family were the most
abundant OTUs. In contrast, C. aerofaciens was the most abundant
discriminatory OTU in the chronic RSP group without significant
BMI gain. Taken together, these results suggest that alterations in
the membership of Firmicutes and Actinobacteria phyla may drive
overall major changes in the gut microbiota in relation to long-
term RSP treatment. In contrast, alterations in the membership of
Firmicutes and Proteobacteria may be linked to weight gain
following long-term RSP treatment. This raises the possibility for
Actinobacteria to be used for the development of novel
therapeutics (prebiotics or probiotics) to prevent or reverse
weight gain following RSP treatment. Indeed, it has been shown
that Bacteriodales species not only ameliorate gut abnormalities
(often found in individuals with psychiatric disorders) but may also
restore social and behavioral impairments.32–34
Gut bacterial metabolic pathways have also been linked to
obesity.13,35 In fact, bacterial fermentation of complex carbohy-
drates and proteins produce short-chain fatty acids in the
proximal colon, optimizing caloric harvest from the diet.13 Short-
chain fatty acids directly provide energy to colonocytes, and
absorption into the portal circulation stimulates adipogenesis.19,28
In addition, short-chain fatty acids are believed to control
anorectic hormone (peptide YY and glucagon-like peptide-1)
release or production through the free fatty acid receptor 2 and
free fatty acid receptor 3.36 In our study, higher levels of KEGG-
associated pathways for butyrate and propionate metabolism
were found within the RSP treatment group compared with
psychiatric controls (Figure 4), suggesting that the gut micro-
biome of these individuals may have higher levels of short-chain
fatty acids production, potentially leading to weight gain.
Our analysis using PICRUSt also found that the microbiota of
participants treated chronically with RSP were enriched for KEGG
orthologs affecting tryptophan metabolism (Figure 4). Tryptophan
and its metabolite, 5-hydroxytryptamine or serotonin, are both
critical to a number of physiological processes, including affective
regulation and energy homeostasis. Growing evidence has also
implicated neurotransmitters in bacterial signaling, further sup-
porting the vast connectivity of the microbiome–gut–brain
axis.20,37 Specifically, gut bacteria are essential to the normal
development of peripheral and central serotonin signaling path-
ways in the host.38 Moreover, probiotic administration has been
shown to influence the availability of tryptophan, suggesting that
microbiota manipulation could be a valid therapeutic strategy to
modulate central nervous system signaling.39 In light of our
findings, we speculate that alterations in tryptophan metabolism
in the gut may mediate, at least in part, SGA-induced weight gain.
Altered tryptophan metabolism may also affect the therapeutic
benefit of RSP treatment.
This study has several limitations that must be acknowledged.
First, the sample size of both studies was relatively small. This may
have led to false-positive results. However, in light of the
preclinical findings reviewed earlier and the apparent consistency
in the pattern of change in bacterial composition across both
human studies (that is, decreased Bacteroidetes:Firmicutes ratio),
it is likely that our findings reflect a true effect of RSP treatment. It
may be possible that changes in bacterial composition reflected
an earlier change in dietary intake induced by RSP. However, the
dietary data collected identified no differences between the
groups. Polypharmacy, which is often observed in SGA-treated
children, may additionally have a role in altering the microbiome.
However, neither psychostimulant nor selective serotonin reup-
take inhibitor use was associated with changes in gut bacterial
composition in our participants (Supplementary Figure 2). None-
theless, our findings require replication in a larger cohort,
including females and in the absence of polypharmacy. Moreover,
as diet has a pivotal role in shaping the gut microbiome, an
evaluation of the impact of the western diet on RSP-induced
weight gain will be critical for future studies to undertake.
Taken together, our findings offer preliminary evidence that the
human gut microbiome is altered in patients treated chronically
with RSP and may be associated with weight gain. Significant
alterations in the microbiome were seen at the phyla level
following both acute and chronic exposure to RSP. In addition,
discriminatory genera (OTUs) were identified, which may help
inform efforts to develop probiotics as a therapeutic. Prospective
studies in both humans and mice are underway to further
investigate the basis of these findings.
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